Suchergebnisse - "Shimamura, Shoko"

PubPharm (8)

1

Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer : a case report

enthalten in: Translational lung cancer research | 2024

von Xu, S. | Shukuya, T. | Shimamura, S. | +11

2

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma

enthalten in: Thoracic cancer | 2023

von Kanamori, K. | Suina, K. | Shukuya, T. | +17

3

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines

enthalten in: Cancers | 2023

von Xu, S. | Miura, K. | Shukuya, T. | +14

4

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma

enthalten in: Thoracic Cancer | 2023

von Kanamori, K. | Suina, K. | Shukuya, T. | +17

5

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC : A Systematic Review and Meta-Analysis

enthalten in: JTO clinical and research reports | 2022

von Xu, S. | Shukuya, T. | Tamura, J. | +8

6

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?

enthalten in: BMC cancer | 2022

von Shimamura, S. | Shukuya, T. | Asao, T. | +10

7

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

enthalten in: BMC cancer | 2022

von Shimamura, S. | Shukuya, T. | Asao, T. | +10

8

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

enthalten in: BMC cancer | 2022

von Shimamura, S. | Shukuya, T. | Asao, T. | +10

1
[1]